Loading patent…
AssigneesThe Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
InventorsMeromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
Estimating the term…
The present invention is generally directed to identifying genes and cell types that are correlated with tumor progression in the tumor microenvironment. PENK was identified as a therapeutic target that is positively correlated with tumor time and size. Targeting PENK can enhance anti-tumor immunity. Opioid signaling can be modulated to enhance anti-tumor immunity. The present invention is also generally directed to interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer.
An isolated immune cell genetically modified ex vivo to decrease or eliminate expression or activity of opioid growth factor receptor (OGFr);
(canceled)
(canceled)
(canceled)
A method of enhancing anti-tumor immunity in a subject in need thereof comprising administering one or more agents capable of inhibiting opioid growth factor receptor (OGFr) signaling;
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of monitoring tumor progression in a subject in need thereof comprising detecting expression of one or more genes selected from Table 2 or optionally, wherein the one or more genes is proenkephalin (PENK) or its proteolytic derivatives.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.